title: Inflammation-Triggered Cancer Immunotherapy by Programmed Delivery of CpG and Anti-PD1 Antibody.
abstract: Inflammation-triggered combination delivery of anti-PD-1 antibody and CpG oligodeoxynucleotides (CpG ODNs) has been demonstrated to prevent cancer relapse utilizing postsurgical inflammatory response. The controlled release of anti-PD1 and CpG ODN by CpG DNA-based "nano-cocoons" can induce considerable immune response, which in turn significantly prolongs the survival time of mice.
authors: Joint Department of Biomedical Engineering, University of North Carolina at Chapel Hill and North Carolina State University, Raleigh, NC, 27695, USA.|Division of Molecular Pharmaceutics and Center for Nanotechnology in Drug Delivery, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA.
authors: Chao
authors: C
authors: Wang
authors: Joint Department of Biomedical Engineering, University of North Carolina at Chapel Hill and North Carolina State University, Raleigh, NC, 27695, USA.|Division of Molecular Pharmaceutics and Center for Nanotechnology in Drug Delivery, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA.
authors: Wujin
authors: W
authors: Sun
authors: Joint Department of Biomedical Engineering, University of North Carolina at Chapel Hill and North Carolina State University, Raleigh, NC, 27695, USA.|Division of Molecular Pharmaceutics and Center for Nanotechnology in Drug Delivery, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA.
authors: Grace
authors: G
authors: Wright
authors: Joint Department of Biomedical Engineering, University of North Carolina at Chapel Hill and North Carolina State University, Raleigh, NC, 27695, USA.|Division of Molecular Pharmaceutics and Center for Nanotechnology in Drug Delivery, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA.|Department of Radiation Oncology, University of North Carolina, Chapel Hill, NC, 27599, USA.
authors: Andrew Z
authors: AZ
authors: Wang
authors: Joint Department of Biomedical Engineering, University of North Carolina at Chapel Hill and North Carolina State University, Raleigh, NC, 27695, USA. zgu@email.unc.edu.|Division of Molecular Pharmaceutics and Center for Nanotechnology in Drug Delivery, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA. zgu@email.unc.edu.|Department of Medicine, University of North Carolina School of Medicine, Chapel Hill, NC, 27599, USA. zgu@email.unc.edu.
authors: Zhen
authors: Z
authors: Gu
mesh_terms: D000276:Adjuvants, Immunologic; D000818:Animals; D000906:Antibodies; D018899:CpG Islands; D007167:Immunotherapy; D007249:Inflammation; D051379:Mice; D009369:Neoplasms / Q000628:therapy*; D061026:Programmed Cell Death 1 Receptor / Q000276:immunology*
chemical_list: D000276:Adjuvants, Immunologic; D000906:Antibodies; D061026:Programmed Cell Death 1 Receptor
keywords: CpG; anti-PD1; cancer immunotherapy; drug delivery; nanobiotechnology